Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

390 recalls · Class II, newest first

Class II · Moderate risk

Zicam

CGMP Deviations; FDA inspection of the contract manufacturer noted out of limit results for microbiological testing

Ongoing Microbial contamination Church & Dwight Co., Inc. D-0790-2026
Class II · Moderate risk

Semaglutide

CGMP Deviations This recall has been initiated due to failing to complete process validation and bacterial endotoxin method validation before distribution

Ongoing Microbial contamination Harbin Jixianglong Biotech Co., Ltd. NDC 84385-106-01 D-0380-2026
Class II · Moderate risk

Semaglutide

CGMP Deviations This recall has been initiated due to failing to complete process validation and bacterial endotoxin method validation before distribution

Ongoing Microbial contamination Harbin Jixianglong Biotech Co., Ltd. NDC 84385-106-01 D-0379-2026
Class II · Moderate risk

Decitabine for Injection 50mg per vial

CGMP Deviations: Out of Specification for Total Aerobic Microbial Count (TAMC) test for unfiltered bulk for decitabine for injection.

Ongoing Microbial contamination Sun Pharmaceutical Industries INC NDC 47335-361-40 D-0582-2024
Class II · Moderate risk

Febuxostat Tablets 80mg

CGMP Deviations: Microbial contamination was reported in stagnant water in the duct of the manufacturing equipment.

Ongoing Microbial contamination Sun Pharmaceutical Industries INC NDC 16714-060-01 D-0369-2024
Class II · Moderate risk

Febuxostat Tablets 40mg

CGMP Deviations: Microbial contamination was reported in stagnant water in the duct of the manufacturing equipment.

Ongoing Microbial contamination Sun Pharmaceutical Industries INC NDC 16714-059-01 D-0368-2024
Class II · Moderate risk

Fexofenadine Hydrochloride Tablets

CGMP Deviations: Microbial contamination was reported in stagnant water in the duct of the manufacturing equipment.

Completed Microbial contamination Sun Pharmaceutical Industries INC NDC 51660-998-30 D-0273-2024
Class II · Moderate risk

Niacin Extended-Release Tablets

CGMP Deviations: Microbial contamination was reported in stagnant water in the duct of the manufacturing equipment.

Completed Microbial contamination Sun Pharmaceutical Industries INC NDC 47335-539-81 D-0270-2024

Recalls by year